Cellular Immunotherapy

Generating Cellular Therapies On-Site at UH Seidman Cancer Center

Immunotherapy is the next frontier in cancer therapy. It uses the body’s immune system to fight cancer. At University Hospitals Seidman Cancer Center, we provide cellular immunotherapy on-site to treat patients more quickly and effectively.

Types of Cellular Immunotherapy for Cancer

Why Choose UH Seidman Cancer Center?

• The Wesley Center for Immunotherapy at UH Seidman Cancer Center is one of a select few facilities in the U.S. that develop CAR T-cell therapies, NK cell therapies and other cellular-based therapies on-site. Treatment can begin in eight days compared to 12 to 30 days commercially. In some cases, we can produce CAR T-cells within 24 hours and infuse them back into the patient about a week later.
• UH Seidman Cancer Center is at the forefront of research to test and develop cellular immunotherapies.
• UH Seidman Cancer Center is an NCI-designated Case Comprehensive Cancer Center, one of 57 such cancer centers nationally. We’re rated “Exceptional,” a rating only seven NCI-designated comprehensive cancer centers hold.
• UH Seidman Cancer Center has been rated one of the best cancer hospitals in the country for more than 20 years by U.S. News & World Report.
• UH Seidman Cancer Center is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT). We’re also a core member the Bone & Marrow Transplant Clinical Trials Network (BMT CTN).
• We work closely with University Hospitals Rainbow Babies & Children’s Hospital, a leading pediatric hospital, and have a specialized adolescent and young adult (AYA) cancer program.
• UH Seidman Cancer Center has a 30-bed inpatient unit specializing in the treatment of hematologic malignancies.
• UH Seidman Cancer Center is involved in pioneering outpatient administration of cell-based immunotherapy and stem cell transplant. When it is an option, outpatient treatment offers many advantages for patients.

Wesley Center for Immunotherapy at UH Seidman Cancer Center

The Wesley Center for Immunotherapy is named in honor of Kimberly and Joseph Wesley. The Wesley family donated $10 million to support groundbreaking research that brings new, life-extending immunotherapy treatments to patients.

The center, which generates CAR T-cell, NK cell and other cell-based therapies on-site, gives patients access to the latest therapies more quickly. Many patients start treatment in eight days, compared to a national average of 12 to 30 days. This allows UH Seidman Cancer Center physicians to deliver therapy in a timely manner to more patients than would otherwise be possible.

University Hospitals is one of less than a dozen academic medical centers to develop CAR T-cells for human use and is the nation’s only National Center for Regenerative Medicine.